Exelon Corp. reported a change in insider beneficial ownership for Matthew C. Rogers, a member of the company’s board of directors, with the reported event dated June 30, 2026. The filing concerns derivative securities in the form of “phantom share equivalents” tied to Exelon stock, rather than a conventional open-market purchase or sale of common shares. The reported change relates to Rogers’ Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan. According to the explanatory note, the phantom share equivalents are designed to be settled in cash on a 1-for-1 basis when Rogers’ service on Exelon’s board ends. In other words, the units track Exelon share value for deferred-compensation purposes, but they do not represent immediately issued common stock. The filing notes that Rogers’ balance includes 7 additional phantom share equivalents that were accrued through automatic dividend reinvestment. No transaction price, open-market trade, option exercise, vesting schedule, or transaction code is provided in the supplied text, and the document does not state the total number of phantom share equivalents beneficially owned after the reported change. The report was signed on July 1, 2026, by David T. Skinner as attorney-in-fact for Rogers. The significance of the filing is that it reflects an automatic, plan-related increase in Rogers’ deferred Exelon-linked holdings, rather than an active insider purchase or sale of Exelon common stock.